Overview

Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding

Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
0
Participant gender:
All
Summary
The investigators studied the renal function index level in terlipressin treated cirrhotic patients with upper-gastrointestinal bleeding at different time point.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Changhai Hospital
Treatments:
Somatostatin
Terlipressin
Criteria
Inclusion Criteria:

- Diagnosied as cirrhosis with upper gastrointestinal bleeding 18≤age≤70 Varicose vein
rupture occurred within 24 hours, Without drug, endoscopy or interventional therapy
Can read, understand and sign informed consent

Exclusion Criteria:

- Pregnant women, lactating women; Serious cardiovascular disease: history of acute
cardiac infarction, heart block, heart failure, arterial hypertension(（SBP>170mmHg
and/ or DBP>100mmHg） Occlusive lower extremity venous disease Asthma, chronic
obstructive pulmonary disease Have serious or unable to control other organ diseases;
Cerebrovascular disease; Age ≥70 years old Known to be allergic to therapeutic drugs
Chronic kidney disease Weight ≤40kg